SCP Acquires DSS from Clario


SCP acquisition of DSS from Clario, a portfolio company of Astorg and Nordic Capital


Stanley Capital Partners LLP (“SCP”) has announced the acquisition of Drug Safety and Pharmacovigilance Services Solutions (“DSS”), a leading global provider of pharmacovigilance, from Clario, a portfolio company of Astorg and Nordic Capital.

Baird served as the exclusive financial advisor to Stanley Capital Partners LLP on this transaction.


SCP is a European and United States-focused mid-market private equity firm using research and technology to identify opportunities in the growing sustainable investment sectors of Resource Efficiency, Healthcare and Technology. SCP targets businesses with Enterprise Values of $250mn to $2.5bn or more. In majority and minority transactions, SCP partners with management teams to transform companies through growth via technology and operational change and market consolidation. SCP was founded in 2019 by Simon Cottle, James Brooks and Patrick Hargutt and has a team of 10 professionals working closely together with its Leader Network and investor, sector and technology partners. DSS represents the 4th investment that SCP has led since its formation in 2019, evidencing SCP’s strong ability to originate investment opportunities and deploy capital.

DSS is a leader in providing outsourced services to support clinical safety and pharmacovigilance commitments. Services to these clients span the full range of drug safety and pharmacovigilance services, which involves collecting, detecting, evaluating, assessing, and disseminating data on adverse effects associated with clinical and commercial medicinal products. DSS also leverages its industry experience to provide advisory support on best practices in the management, sourcing and systems deployed in the safety arena. As part of this, DSS has designed and implemented a range of proprietary automation technologies, which have served as technology enablers in this space. DSS is headquartered in Delaware, and has over 2,500 staff located in the EU, United States, Japan, and India, supporting over 35 long-term clients.

Clario delivers the leading endpoint technology solutions for clinical trials. Through experience gained from over 19,000 clinical trials and 870 regulatory approvals, Clario fuses scientific expertise and global scale into the broadest endpoint technology platform to enable pharmaceutical, biotech and medical device partners to transform lives. Through Trial Anywhere™, Clario has mastered the ability to generate rich evidence across all trial models: decentralized, hybrid and site-based clinical trials. With 30 facilities in nine countries across North America, Europe and Asia Pacific, Clario’s global team of science, technology and operational experts has delivered the richest clinical evidence for nearly 50 years. Clario is headquartered in Philadelphia, Pennsylvania.

Astorg is a global private equity firm with over €15 billion of assets under management. Astorg works with entrepreneurs and management teams to acquire market leading global companies headquartered in Europe or the United States, providing them with the strategic guidance, governance and capital they need to achieve their growth goals. Enjoying a distinct entrepreneurial culture, a long-term shareholder perspective and a lean decision-making body, Astorg has valuable industry expertise in healthcare, software, technology, business services and technology-based industrial companies. Astorg has offices in London, Paris, New York, Frankfurt, Milan and Luxembourg.

Nordic Capital is a leading private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a long history. Focus sectors are Healthcare, Technology & Payments, Financial Services, and selectively, Industrial & Business Services. Key regions are Europe and globally for Healthcare and Technology & Payments investments. Since inception in 1989, Nordic Capital has invested more than EUR 19 billion in over 120 investments. The most recent entities are Nordic Capital X with EUR 6.1 billion in committed capital and Nordic Capital Evolution with EUR 1.2 billion in committed capital, principally provided by international institutional investors such as pension funds. Nordic Capital Advisors have local offices in Sweden, the United Kingdom, the United States, Germany, Denmark, Finland, Norway and South Korea. Nordic Capital is headquartered in Stockholm, Sweden.

SCP acquisition of DSS from Clario, a portfolio company of Astorg and Nordic Capital

February 2022
Stanley Capital Partners LLP
M&A - Buyside
Pharmaceutical Services
Target Geography
North America
Acquiror Geography